Welcome to IgMin Research – an Open Access journal uniting Biology, Medicine, and Engineering. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.
At IgMin Research, we bridge the frontiers of Biology, Medicine, and Engineering to foster interdisciplinary innovation. Our expanded scope now embraces a wide spectrum of scientific disciplines, empowering global researchers to explore, contribute, and collaborate through open access.
Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.
IgMin Publications Inc., Suite 102, West Hartford, CT - 06110, USA
Our purpose is to support the convergence of fields for a faster dissemination of knowledge.
Biography
Martina Rudelius, MD, PhD is a highly respected Associate Professor and Senior Consultant (“Leitende Oberärztin”) in Clinical Pathology at the Institute of Pathology, Ludwig‑Maximilians‑Universität (LMU) Munich, Germany, where she also serves as head of the Rudelius Lab .
Her team specializes in spatial molecular tumor biology, employing advanced, multiparametric single-cell techniques. These include multispectral imaging, spatial transcriptomics, spatial metabolomics and single-cell RNA sequencing to study tumor–microenvironment interactions, such as tumor-infiltrating lymphocytes and cancer-associated fibroblasts—key determinants of therapeutic vulnerability and resistance. Additionally, her group investigates cardiovascular pathology, focusing on the immune and smooth-muscle cell dynamics that contribute to atherosclerotic plaque instability and consequent myocardial infarction risk.
Dr. Rudelius has an impressive publication record with over 258 peer-reviewed studies and more than 10,600 citations, reflecting her extensive impact in imaging, cancer biology, cell signaling, and molecular pathology. Notable contributions include high-impact work in lymphoma biology, stem cell tracking, and advanced molecular imaging techniques.
Her research bridges academic innovation and translational medicine, collaborating closely with clinical experts and national/international networks such as the Clinical Cancer Center Munich, DKTK, and the German Lymphoma Alliance. This synergy ensures that discoveries from the Rudelius Lab are rapidly integrated into diagnostic and therapeutic strategies.
Martina Rudelius embodies scientific excellence through her leadership, methodological innovation, and dedication to unraveling complex disease biology—making her a driving force in modern pathology and translational cancer research at LMU Munich.
Research Interest
Martina Rudelius’ research interests lie at the intersection of molecular pathology, cancer biology, and spatial cellular profiling. She focuses on deciphering tumor–microenvironment interactions using cutting-edge single-cell technologies such as spatial transcriptomics, multiplex immunofluorescence, and spatial metabolomics. Her work aims to unravel the mechanisms of immune evasion, therapeutic resistance, and tumor progression in hematologic malignancies and solid tumors. A major area of interest is the spatial mapping of tumor-infiltrating immune cells and stromal components, particularly cancer-associated fibroblasts, to identify predictive biomarkers and therapeutic targets. Additionally, she investigates cardiovascular pathology, with an emphasis on the role of immune cells and vascular remodeling in plaque instability and atherosclerosis. Dr. Rudelius is deeply engaged in translational research, collaborating with national and international networks to bridge basic discoveries with clinical applications. Her goal is to enhance diagnostic precision and guide personalized treatment strategies through integrative, spatially resolved pathology.
Open Access Policy refers to a set of principles and guidelines aimed at providing unrestricted access to scholarly research and literature. It promotes the free availability and unrestricted use of research outputs, enabling researchers, students, and the general public to access, read, download, and distribute scholarly articles without financial or legal barriers. In this response, I will provide you with an overview of the history and latest resolutions related to Open Access Policy.
Mastocytosis, a hematological neoplasm, manifests with diverse clinical, molecular, and histomorphological features. This review explores the different subtypes of mastocytosis, focusing on the role of molecular pathology and histomorphology in diagnosing systemic mastocytosis (SM). Systemic mastocytosis is characterized by histologically confirmed extracutaneous involvement, presenting a diagnostic challenge due to its rarity and diverse subtypes, ranging from occult SM to mast cell leukemia. The complexity of accurate SM diagnosis underscores... the necessity for a comprehensive understanding of the disease spectrum. Mastocytosis emerges as a rare, multifaceted disease, predominantly affecting children in the cutaneous form and adults in the systemic variant. The review advocates a multidisciplinary diagnostic approach involving experienced hematopathologists and haematooncologists, employing conventional histomorphology, immunohistochemistry, and molecular techniques. This holistic approach is crucial for accurate diagnosis, especially in light of recent therapeutic advances, particularly the growing importance of tyrosine kinase inhibitors (TKI) in the management of mastocytosis.
0000-0002-7332-4589 
